2013


To access this material please log in or register

Register Authorize
2013/№2

Peculiarities in development of chronic heart failure in patients with hypertrophic cardiomyopathy

Khabarova N. V.
State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: hypertrophic cardiomyopathy, medicinal treatment, prognosis, surgical therapy, CHF

DOI: 10.18087 / rhfj.2013.2.1809

The review is focused on peculiarities of CHF development in hypertrophic cardiomyopathy (HCMP), drug and surgical methods of treatment, and markers of unfavorable prognosis.
  1. Wigle ED, Rakovski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation. 1995;92 (7):1680–1692.
  2. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287 (10):1308–1320.
  3. Maron BJ, McKenna WJ, Danielson GK et al. American College of Cardiology / European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42 (9):1687–1713.
  4. Olivotto I, Maron MS, Adabag AS. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyo­pathy. J Am Coll Cardiol. 2005;46 (3):480–487.
  5. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF / AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardio­logy Foundation / American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58 (25):e212–260.
  6. Ommen SR, Maron BJ, Olivotto I et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46 (3):470–476.
  7. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of Hypertrophic cardiomiopathy. N Engl J Med. 1997;336 (11):775–785.
  8. Melacini P, Basso C, Angelini A et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010;31 (17):2111–2123.
  9. Maron B, Tholakanahalli V, Zenovich A et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation. 2004;109 (8):984–989.
  10. Maron MS, Oliviotto I, Betocchi S et al. Effect of left ventricular outflow tract obstruction on clinical outcome in Hypertrophic cardiomiopathy. N Engl J Med. 2003;348 (4):295–303.
  11. Autore C, Bernabo P, Barilla CS et al. The prognostic importance of left ventricular outflow obstruction in Hypertrophic cardiomio­pathy varies in relation to the severity of symptoms. J Am Coll Cardiol. 2005;45 (7):1076–1080.
  12. Olivotto I, Cecchi F, Casey SA et al. Impact of atrial fibrillation on the clinical course of Hypertrophic cardiomiopathy. Circulation. 2001;104 (21):2517–2524.
  13. Maron BJ, Olivotto I, Bellone P et al. Clinical profile of stroke in 900 patients with Hypertrophic cardiomiopathy. J Am Coll Cardiol. 2002;39 (2):301–307.
  14. Maron BJ, Spiritto P, Green KJ et al. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with Hypertrophic cardiomiopathy. J Am Coll Cardiol. 1987;10 (4):733–42.
  15. Maron MS, Zenovich AG, Casey SA et al. Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in Hypertrophic cardiomiopathy. Am J Cardiol. 2005;95 (11):1329–1333.
  16. Shah PM, Taylor RD, Wong M et al. Abnormal mitral valve coaptation in Hypertrophic obstructive cardiomiopathy: proposed role of systolic anterior motion of mitral valve. Am J Cardiol. 1981;48 (2):258–262.
  17. Maron BJ, Harding AM, Spirito P et al. Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with Hypertrophic cardiomiopathy. Circulation. 1983;68 (2):282–293.
  18. Klues HG, Roberts WC, Maron BJ et al. Anomalous insertion of pa­pillary muscle directly into anterior mitral leaflet in Hypertrophic cardiomiopathy: significance in producing left ventricular outflow obstruction. Circulation. 1991;84 (3):1188–1197.
  19. Braunwald E, Lambrew C, Rockoff S et al. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients with emphasis on the natural history. Circulation. 1964; 30 (Suppl IV): 3–119.
  20. Maron BJ, Maron MS, Wigle ED et al. The 50‑years history, controvercy, and clinical implications of left ventricular outflow obstruction in Hypertrophic cardiomiopathy: from idiopathic Hypertrophic subaortic stenosis to hypertropic cardiomiopathy. J Am Coll Cardiol. 2009;54 (3):191–200.
  21. Paz R, Jortner R, Tunick PA et al. The effect of the ingestion of etanol on obstruction of the left ventricular outflow tract in Hypertrophic cardiomyopathy. N Engl J Med. 1996;335 (13):938–941.
  22. Maron MS, Olivotto I, Zenovich AG et al. Hypertrophic cardiomio­pathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114 (21):2232–2239.
  23. Spirito P, Seidman CE, McKenna WJ et al. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336 (11):775–785.
  24. Feifer MA, Vlahakes GJ. Management of symptoms in Hypertrophic cardiomiopathy. Circulation. 2008;117 (3):429–439.
  25. Bonow RO, Rosing DR, Bacharach SL et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with Hypertrophic cardiomiopathy. Circulation. 1981;64 (4):787–796.
  26. Epstein SE, Rosung DR. Verapamil: its potential for causing serious complications in patients with Hypertrophic cardiomiopathy. Circulation. 1981;64 (3):437–441.
  27. Nistri S, Olivotto I, Maron MS et al. Beta blockers for prevention of exercise-indused left ventricular outflow tract obstruction in patients with hypertrophic cardiomiopathy. Am J Cardiol. 2012;110 (5):715–719.
  28. Kimbal BP, Bui S, Wigle ED. Acute dose-response effects of intravenous disopyramide in Hypertrophic obstructive cardiomiopathy. Am Heart J. 1993;125 (6):1691–1697.
  29. Sherrid M, Delia E, Dwyer E. Oral disopyramide therapy for obstructive Hypertrophic cardiomiopathy. Am J Cardiol. 1988;62 (16):1085–1088.
  30. Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic Hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. Ann Surg. 1961;154:181–189.
  31. Бокерия Л. А., Гудкова Р. Г. Сердечно-сосудистая хирургия – 2007. Болезни и врожденные аномалии системы кровообращения. – М., НЦССХ им. А. Б. Бакулева РАМН, 2007.–144.
  32. Maron BJ. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive Hypertrophic cardiomiopathy. Circulation. 2007;116 (2):196–206.
  33. Maron BJ, Yacoub M, Dearani JA. Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients. Eur Heart J. 2011;32 (9):1055–1058.
  34. Ball W, Ivanov J, Rakovski H et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol. 2011 Nov;58 (22):2313–2321.
  35. Ommen SR, Maron BJ, Olivotto I et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive Hypertrophic cardiomiopathy. J Am Coll Cardiol. 2005;46 (3):470–476.
  36. ten Cate FJ, Soliman OI, Michels M et al. Long-term outcome of alcohol septal ablation in patients with obstructive Hypertrophic cardiomiopathy: a word of caution. Circ Heart Fail. 2010;3 (3):362–369.
  37. Agraval S, Tuzcu EM, Desai MY et al. Updated meta-analisis of septal alcohol ablation versus myectomy for Hypertrophic cardiomiopathy. J Am Coll Cardiol. 2010 Feb;55 (8):823–834.
  38. Noseworthy PA, Rosenberg MA, Feifer MA et al. Ventricular arrhythmia following alcohol septal ablation for obstructive Hypertrophic cardiomiopathy. Am J Cardiol. 2009;104 (1):128–132.
  39. Бокерия Л. А. Хирургическая коррекция гипертрофической обструктивной кардиомиопатии после процедуры чрезкатетерной эмболизации септальных ветвей. – М.: Издательство НЦССХ им. А. Н. Бакулева, 2008. – 144 с.
  40. Sorajja P, Valeti U, Nishimura RA et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomiopathy. Circulation. 2008;118 (2):131–139.
  41. Olivotto I, Ommen SR, Maron BJ et al. Surgical myectomy versus alcohol septal ablation for obstructive Hypertrophic cardiomiopathy: will there ever be a randomized trial? J Am Coll Cardiol. 2007;50 (9):831–834.
  42. Maron BJ, Nishimura RA, McKenna WJ et al. Asesment of permanent dual-chember pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: a randomized double-blinde, crossover study. Circulation. 1999;99 (22):2927–2933.
  43. Беленков Ю. Н., Привалова Е. В., Каплунова В. Ю. Гипертрофи­ческая кардиомиопатия. – М.: Геотар-Медиа, 2011. – 386 с.
  44. Geske JB, Sorajja P, Nishimura RA, Ommen SR. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation. 2007;116 (23):2702–2708.
  45. Alvares RF, Goodvin JF. Non-invasive assessment of diastolic function in Hypertrophic cardiomiopathy on and off beta adrenergic blocking drugs. Br Heart J. 1982;48 (3):204–212.
  46. Bourmayan C, Razavi A, Fournier C et al. Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echocardiographic study. Am Heart J. 1985;109 (6):1311–1316.
  47. Udelson JE, Bonow RO, O’Gara PT et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with Hypertrophic cardiomiopathy. Circulation. 1989;79 (5):1052–1060.
  48. Bonow RO, Frederick TM, Bacharach SL et al. Atrial systole and left ventricular filling in Hypertrophic cardiomiopathy: effect of verapamil. Am J Cardiol. 1983;51 (8):1386–1391.
  49. Kass DA, Wolff MR, Ting CT et al. Diastolic compliance of hyper­trophied ventricle is not acutely altered by pharmacologic agents influencing active processes. Ann Intern Med. 1993;119 (6):466–473.
  50. Maron BJ. Hypertrophic cardiomiopathy centers. Am J Cardiol. 2009;104 (8):1158–1159.
  51. Ahmad F, Seidman JG, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet. 2005;6:185–216.
  52. Oliviotto I, Maron BJ, Ahhelbaum E et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in Hypertrophic cardiomio­pathy. Am J Cardiol. 2010;106 (2):261–267.
  53. Maron MS, Kalsmith BM, Udelson JE et al. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3 (5):574–579.
  54. Topilsky Y, Pereira NL, Shah DK et al. left ventricular assist device therapy in patients with restrictive and Hypertrophic cardiomiopathy. Circ Heart Fail. 2011;4 (3):266–275.
Khabarova N.V. Peculiarities in development of chronic heart failure in patients with hypertrophic cardiomyopathy. Russian Heart Failure Journal. 2013;14 (2):105-108

To access this material please log in or register

Register Authorize
Ru En